Neuroleptic-Related Dyskinesias in Children and Adolescents
J Clin Psychiatry 2001;62(12):967-974
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Few studies have investigated the comparative risk
of neuroleptic-related dyskinesias in children and adolescents receiving typical
versus newer, atypical antipsychotics. This prospective study was completed
to test whether clinical use of atypical antipsychotics is associated with less
risk for developing neuroleptic-related dyskinesias than clinical use of typical
neuroleptics in an unselected heterogeneous population of seriously emotionally
disturbed youths admitted to acute residential treatment. We also tested a novel
model of predictive risk for neuroleptic-related dyskinesias in children and
Method: 102 children and adolescents receiving typical neuroleptics,
atypical antipsychotics, or the combination were studied. Youths developing
neuroleptic-related dyskinesias were compared with youths free of dyskinesias
over a 3-month study period on demographic, diagnostic, and treatment variables.
Logistic regression was utilized to develop a novel model of predictive risk.
Results: Of neuroleptic-treated youths, 5.9% had probable tardive
dyskinesia, a rate less than the prevalence of tardive dyskinesia in chronic
neuroleptic-treated adults. Use of typical neuroleptics was significantly (p
= .03) associated with dyskinesia compared with use of atypical antipsychotics.
Four variables including IQ, initial Abnormal Involuntary Movement Scale score,
type of antipsychotic, and cumulative number of risk factors accounted for 35.8%
of the variance when predicting dyskinetic status.
Conclusion: Use of atypical antipsychotics appears to be associated
with less dyskinesia risk than typical neuroleptics in an unselected group of
seriously emotionally disturbed children and adolescents. Results support a
cumulative risk model of neuroleptic-related dyskinesia in youths.